APA (7th ed.) Citation

A, S., M, Y., NA, Z., V, N., BA, S., B, S., . . . KK, Z. (2026). Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: A pooled analysis. The oncologist, 31(6), . https://doi.org/10.1093/oncolo/oyag172

Chicago Style (17th ed.) Citation

A, Saxena, et al. "Prevalence of Adverse Events Following T-cell Redirecting Therapies in Patients with Metastatic Castration-resistant Prostate Cancer: A Pooled Analysis." The Oncologist 31, no. 6 (2026). https://doi.org/10.1093/oncolo/oyag172.

MLA (9th ed.) Citation

A, Saxena, et al. "Prevalence of Adverse Events Following T-cell Redirecting Therapies in Patients with Metastatic Castration-resistant Prostate Cancer: A Pooled Analysis." The Oncologist, vol. 31, no. 6, 2026, https://doi.org/10.1093/oncolo/oyag172.